Prof. Lugui Qiu is a leading hematologist specializing in multiple myeloma (MM), B-cell lymphoma, and chronic lymphocytic leukemia (CLL) in China. He is the chief expert on lymphoma and myeloma. He served as Professor and Director of the Department of Lymphoma & Myeloma at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences from 2000 to 2024. He is a Board Member of the International Myeloma Society (IMS) and Committee Member of the International Myeloma Working Group (IMWG).
Dr. Qiu has been leading clinical and translational research in lymphoma and myeloma for over two decades, establishing state of art diagnostic and treatment systems that significantly improved patient outcomes. He conducted more than 30 clinical trials and promoted 10 new drugs for lymphoma and myeloma on market in China. His studies on clinical and translational research have resulted in over 180 SCI-indexed publications, including in NEJM, Lancet/Lancet Oncology, JCO, JAMA Oncology, Blood, Leukemia, Clinical Cancer Research, and JCI, etc., and have received broad international recognition.
He has played a key role in developing national guidelines on lymphoma and myeloma in China. Prof. Qiu has received multiple national awards, secured nearly 30 major grants, and mentored over 80 graduate students. His work has greatly advanced the standard of care and research in hematologic malignancies in China.
MS, Hematology, Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS), Tianjin, China, 1988-1991
M.D., Medicine, Jiangxi Medical College (Medical College of Nanchang University), Nanchang, China, 1980-1985
Doctoral supervisor, Peking Union Medical College, 2002-
Tenured associate professor, Peking Union Medical College, 2021-
Department director, Chief physician, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2001-2024
Associate chief physician, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1994-2000
Research Associate, University of Louisville, USA, 1996-1999
Attending physician, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1991-1994
Resident doctor, Jiangxi Medical College, First Affiliated Hospital, 1985-1988
PRINCIPAL HONORS, AWARDS:
2022 The Jiu San Society, Tianjin, Person of the Year
2021 Tianjin Science and Technology Progress Award, First Award
2020 State Council Special Allowance Expert
2020 Tianjin Great Physician (The first group)
2019 Science and Technology Achievement Award of Ministry of Education, Second Award
2018 Tianjin Science and Technology Progress Award, Second Award
2017 Youth Experts with Outstanding Contribution to National Health and Family Planning Commission
2016 Tianjin Labour Day medal
2008 Tianjin Science and Technology Progress Award, Third Award
2007 Natural Science Award of Ministry of Education, Second Award
2006 The First-level Talents of Tianjin 131 Talent Project
2005 Tianjin Science and Technology Progress Award, Second Award
2004 Tianjin Science and Technology Progress Award, First Award
2003 Tianjin Science and Technology Progress Award, Second Award
MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
2024-Present Chairman, Myeloma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
2019-Present Committee Member, International Myeloma Society, IMS
2014-Present Committee Member, International Myeloma Working Group, IMWG
2017-2021 Editorial Board Member, Blood Advances
2022-Present executive member, The ninth Council of the China Anti-Cancer Association (CACA)
2022-Present Honorary Chairman, Hematology Oncology Committee of CACA
2022-Present Vice Chairman, The 1st committee of Chinese Hospital Association Hematology Branch
2021-Present Vice Chairman, The sixth Council of the Tianjin Anti-cancer Association
2012-Present Editor Board, Chinese Journal of Hematology and other 6 core journals
2019-2022 Chairman, Hematology Oncology Committee of CACA
2006-2016 Member of Hematology Branch Committee, Chinese Medical Association
SELECTED PUBLICATIONS:
1. Yu Y, Li Y, Cui R, Yan Y, Li F, Chen Y, Wang T, Hu X, Feng Y, Yu T, Huang Y, Sun J, Lyu R, Xiong W, Wang Q, Liu W, An G, Sui W, Xu Y, Huang W, Zou D, Wang H, Xiao Z, Wang J, Qiu L*, Yi S. Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study. Signal Transduct Target Ther. 2025 Mar 12;10(1):85.
2. Li C, Zhou K, Hu Y, Zou D, Chen L, Chen B, Liu J, Zhang X, Ren H, Hu K, Liu P, Mi JQ, Li Z, Ding K, Wang D, Wang W, Cai S, Li J, Song Y, Huang H, Qiu L*. Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov 7;10(12):1681–8.
3. Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T. International Myeloma Working Group Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 Aug;25(8):e374-e387. doi: 10.1016/S1470-2045(24)00094-9. Epub 2024 May 28.
4. Yan Y, Yu Y, Xiong W, Wang J, Yao Y, Jia Y, Huang Y, Li Y, Wang T, Lyu R, Sun H, Wang H, Wang Q, Liu W, An G, Sui W, Xu Y, Huang W, Yu Z, Zou D, Hao M, Xiao Z, Wang J, Qiu L*, Yi S. Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia. Clin Cancer Res. 2024 Dec 2;30(23):5483-5493.
5. Gong L, Sun H, Liu L, Sun X, Fang T, Yu Z, Sui W, Xu J, Wang T, Feng F, Lei L, Rui W, Liu Y, Zhao X, An G, Lin X, Qiu L*, Hao M. LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. Haematologica. 2024 Nov 1;109(11):3650-3669.
6. Yan W, Shi L, Xu J, Li L, Cui J, Liu Y, Zhou J, Du C, Yu T, Zhang S, Lv R, Sui W, Deng S, Li X, Du X, Xu Y, Zou D, Qiu L*, Hao M, An G. Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma. Leukemia. 2024 Oct; 38 (10):2235-2245.
7. Cui J, Liu Y, Lv R, Yan W, Xu J, Li L, Du C, Yu T, Zhang S, Deng S, Sui W, Hao M, Yi S, Zou D, Qiu L*, Xu Y, An G. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma. Leukemia. 2024 Jun;38(6):1299-1306. doi: 10. 1038/s41375-024-02237-3.
8. Tang P, Yu Z, Sun H, Liu L, Gong L, Fang T, Sun X, Xie S, An G, Xu Z, Qiu L*, Hao M. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. EBioMedicine. 2024 Feb;100:104961.
9. Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD Jr, Anderson KC, Zhan F, Qiu L*, An G. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. Am J Hematol. 2024 Apr;99(4):523-533.
10. Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, Jiang L, Meng L, Yang Y, Zhou X, Hong Z, Yao Z, Xiao M, Chen L, Mao X, Zhu L, Wang J, Qiu L*, Li C, Zhou J. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 2021 May 27;137(21):2890-2901.
11. Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu*. The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449.
12. Yu Z, Wei X, Liu L, Sun H, Fang T, Wang L, Li Y, Sui W, Wang K, He Y, Zhao Y, Huang W, An G, Meng F, Huang C, Yu T, Anderson KC, Cheng T, Qiu L*, Hao M. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine. 2022 Apr;78:103950.
13. Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, Yang L, Gine E, Clot G, Chen L, Yu Y, Zou D, Wang J, Phan AT, Cui R, Li F, Sun Q, Zhai Q, Wang T, Yu Z, Liu L, Liu W, Lyv R, Sui W, Huang W, Xiong W, Wang H, Li C, Xiao Z, Hao M, Wang J, Cheng T, Bea S, Herrera AF, Danilov A, Campo E, Ngo VN, Qiu L*, Wang L. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283.
14. An G, Zhou D, Cheng S, Zhou K, Li J, Zhou J, Xie L, Jin J, Zhong L, Yan L, Guo H, Du C, Zhong J, Yu Y, Wu B, Qiu L*. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501.
15. Yi S, Yan Y, Jin M, Xiong W, Yu Z, Yu Y, Cui R, Wang J, Wang Y, Lin Y, Jia Y, Zhang D, Wang T, Lv R, Liu W, Sui W, Huang W, Fu M, Xu Y, Deng S, An G, Zou D, Li Z, Shi J, Xiao Z, Wang J, Cheng T, Gale RP, Wang L, Qiu L*. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021 Aug;35(8):2412-2415.
16. Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Tai YT, Anderson KC, Qiu L*, Munshi NC. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 Jul 23;136(4):468-479.
17. An G, Yan Y, Xu Y, Mao X, Liu J, Fan H, Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, Zhao Y, Yuan C, Du X, Wang J, Cheng T, Tai YT, Munshi NC, Qiu L*. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020 Feb;34(2):578-588.
18. Xiong W, Lv R, Li H, Li Z, Wang H, Liu W, Zou D, Qiu L*, Yi S. Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. Blood cancer journal. 2017,7(3):e548.
19. Qin Y, Zhang S, Deng S, An G, Qin X, Li F, Xu Y, Hao M, Yang Y, Zhou W, Chang H, Qiu L*. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017 May;31(5):1123-1135.
20. An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L*, Tai YT, Anderson KC. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016;128(12):1590-603.